Company Overview and News

78
Hong Kong Developers Have a Shiny New Plaything - Bloomberg

2018-06-08 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
BABA HLPPY SOLLY SOLLF 0272 0101 HLPPF

0
Hong Kong developers finalists in battle for US$2.1 billion site in Shanghai shopping heartland

2018-05-31 scmp
Hong Kong developers Shui On Land and Hongkong Land are vying for a prime plot of land in central Shanghai, a move that underscores the rising appeal of China’s top cities among overseas companies.
SUHJY 0017 0016 SHGKF HLPPY SOLLY SHGKY SOLLF 0272 0101 HLPPF SUHJF

1
$1.7 Billion Bet Shows Hong Kong Developers’ on Hunt for Land in China - Bloomberg

2018-05-30 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
HKHGF H78 HLPPY WARFF WARFY HNGKY 0101 HLPPF

0
Hang Lung snaps up prime Hangzhou plot for US$1.7b

2018-05-28 scmp
Earmarked for commercial development, it’s the Hong Kong company’s first purchase in mainland China for five years
HNLGF HLPPY HNLGY 0101 HLPPF 0010

0
Pop-up stores to increase in Hong Kong as rents for retail space continue to rise

2018-05-01 scmp
Analysts say pop-up stores allow retailers and mall operators to gather customers’ response quickly and adjust their business plans to capture opportunities
0017 0014 1972 HLPPY SWROY SWPFF 0101 HLPPF

0
Hang Lung to spend HK$40 million on mall upgrades to woo Mong Kok’s shoppers

2018-03-27 scmp
The appeal of Hang Lung’s Gala Place and Hollywood Plaza malls has been in decline amid a shifting retail landscape, says Knight Frank
0017 HLPPY 0101 HLPPF

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

Silicon Investor Message Boards

This table lists all message boards related to HKEX:0101 / Hang Lung Properties Ltd on message board site Silicon Investor.

0101_ Japan Mutual Fund